The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Teladoc Health Inc (NYSE: TDOC) closed at $9.09 up 8.60% from its previous closing price of $8.37. In other words, the price has increased by $8.60 from its previous closing price. On the day, 12.38 million shares were traded. TDOC stock price reached its highest trading level at $9.29 during the session, while it also had its lowest trading level at $8.29.
Ratios:
For a deeper understanding of Teladoc Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.51. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.59. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Mizuho on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $10.
On November 15, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $14.
Jefferies reiterated its Hold rating for the stock on September 17, 2024, while the target price for the stock was revised from $8 to $10.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 02 ’25 when Catapano Joseph Ronald sold 2,972 shares for $7.88 per share. The transaction valued at 23,434 led to the insider holds 5,361 shares of the business.
DIVITA CHARLES III sold 16,787 shares of TDOC for $127,435 on Sep 11 ’25. The CHIEF EXECUTIVE OFFICER now owns 179,014 shares after completing the transaction at $7.59 per share. On Sep 11 ’25, another insider, DIVITA CHARLES III, who serves as the Officer of the company, bought 16,787 shares for $7.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TDOC now has a Market Capitalization of 1606118144 and an Enterprise Value of 1961589120. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.63 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 0.772 whereas that against EBITDA is 103.887.
Stock Price History:
The Beta on a monthly basis for TDOC is 1.90, which has changed by -0.042149603 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, TDOC has reached a high of $15.21, while it has fallen to a 52-week low of $6.35. The 50-Day Moving Average of the stock is 17.91%, while the 200-Day Moving Average is calculated to be 8.13%.
Shares Statistics:
For the past three months, TDOC has traded an average of 6.70M shares per day and 10230060 over the past ten days. A total of 176.61M shares are outstanding, with a floating share count of 174.68M. Insiders hold about 1.13% of the company’s shares, while institutions hold 73.65% stake in the company. Shares short for TDOC as of 1757894400 were 23817885 with a Short Ratio of 3.56, compared to 1755216000 on 23618236. Therefore, it implies a Short% of Shares Outstanding of 23817885 and a Short% of Float of 15.079999999999998.
Earnings Estimates
The firm’s stock currently is rated by 4.0 analysts. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.23 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.84 and -$1.35 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$0.96, with 4.0 analysts recommending between -$0.93 and -$0.99.
Revenue Estimates
A total of 24 analysts believe the company’s revenue will be $625.86M this quarter.It ranges from a high estimate of $632.7M to a low estimate of $619.6M. As of. The current estimate, Teladoc Health Inc’s year-ago sales were $640.51MFor the next quarter, 24 analysts are estimating revenue of $634.43M. There is a high estimate of $642.65M for the next quarter, whereas the lowest estimate is $621.4M.
A total of 24 analysts have provided revenue estimates for TDOC’s current fiscal year. The highest revenue estimate was $2.53B, while the lowest revenue estimate was $2.5B, resulting in an average revenue estimate of $2.52B. In the same quarter a year ago, actual revenue was $2.57BBased on 24 analysts’ estimates, the company’s revenue will be $2.55B in the next fiscal year. The high estimate is $2.62B and the low estimate is $2.49B.
